Biohaven Ltd. BHVN
Program: BHV-1530
New clinical data with BHV-1530, an FGFR3-directed ADC using a novel TopoIx payload, being presented at ESMO in October 2026
SEC FILING STATEMENTS
ESMO Congress 2026 (October 23–27): biotech companies that stated plans in SEC filings
This list shows what each company wrote in an SEC filing. It does not confirm a presentation time, abstract, or result.
Conference dates: ESMO Congress 2026 · official conference calendar.
Data as of
11 program statements · 5 companies
Eikon Therapeutics, Inc. EIKN
Program: EIK1001
We expect to present updated data from TeLuRide-005 at the 2026 European Society of Medical Oncology, or ESMO, Congress in October 2026.
Program: EIK1003
We plan to present updated data from Cohort 1A at the ESMO Congress 2026 in October 2026.
Program: EIK1003
We plan to present initial clinical data from Cohort 1B at the ESMO Congress 2026 in October.
Program: EIK1003
We plan to present the updated clinical data from Cohort 1C at the ESMO Congress 2026 in October 2026.
Program: EIK1004
We plan to present the first clinical data from this trial at the ESMO Congress 2026 in October.
Program: EIK1005
We plan to present initial clinical data from this trial at the ESMO Congress 2026 in October 2026.
Immatics N.V. IMTX
Program: IMA203CD8
Updated Phase 1 data from IMA203CD8 across multiple PRAME-positive solid tumors will be presented at ESMO Congress 2026.
Program: IMA402
Phase 1b data from IMA402 at the RP2D range across multiple cancers will be presented at ESMO Congress 2026.
Iovance Biotherapeutics, Inc. IOVA
Program: lifileucel
Results will be highlighted in an oral presentation (abstract #3725RO) at the European Society for Medical Oncology (ESMO) meeting in Madrid, Spain, from October 23–27, 2026.
Tango Therapeutics, Inc. TNGX
Program: vopimetostat + RAS(ON) inhibitors
We plan to share data from the Phase 1/2 trial of the combination of vopimetostat plus RAS(ON) inhibitors at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain from October 23-27, 2026.